OA is one of the most common debilitating diseases experienced within an ageing population and constitutes an urgent medical need. Also obesity, a major risk factor, is increasing in prevalence and increasing occurrence of osteoarthritis. Approximately 30% of the global population over 60 years suffers from OA. The estimated OA population in India alone is approximately 30 million (“mn”). OA largely affects weight bearing joints such as the knee joint & hip joint amongst others. Presently, treatment options available include NSAIDs, glucosamine & chondroitin sulphate, Diacerin (IL – 1 inhibitor), Hyaluronic Acid injections (“HA”), steroid injections, autologous chondrocyte transplantation and, ultimately, total knee replacement. Existing treatment options focus on providing temporary pain relief and reducing inflammation during the early stages of the disease without affecting the course of the disease.

Stempeucel® OA has the potential to provide best-in-class pain reduction, improve quality of life, has the potential to regenerate/maintain cartilage and to stall further disease progression for radiology Grade 2 & Grade 3 Osteoarthritis patients.